The thiopurine drug 6-mercaptopurine (6-MP), which has been used for acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) treatment, competes with HPRT1 substrates and thereby inhibits HPRT1 activity30. Here, HPRT1 is linked to acute lymphoblastic leukemia.